Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
      • Scientific Advisory Board
    • Facilities
  • Therapeutic Areas
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Long COVID
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 CR
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-102 SL
      • TNX-1840/TNX-1850
      • TNX-3500
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
May 11, 2015 6:00am EDT

Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update

Mar 20, 2015 11:30am EDT

Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference

Mar 4, 2015 8:40am EST

Tonix Pharmaceuticals to Present at the 27th Annual ROTH Conference

Mar 3, 2015 8:00am EST

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

Mar 2, 2015 8:40am EST

Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum

Feb 9, 2015 1:45pm EST

Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock

Feb 5, 2015 3:00pm EST

Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 4, 2015 1:15pm EST

Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock

Feb 3, 2015 9:02pm EST

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 15, 2015 7:00am EST

Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • …
  • …Page 46
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2022 Tonix Pharmaceuticals Holding Corp.